Search

Displaying results 871 - 880 of 2160 in total
  1. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  2. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    In two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50 x

  3. Drug

    Cytarabine

    go.drugbank.com/drugs/DB00987
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

  4. Drug

    Aminoglutethimide

    go.drugbank.com/drugs/DB00357
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)

  5. Drug

    Levomefolic acid

    go.drugbank.com/drugs/DB11256
    Approved

    Supplementation of levomefolic acid is desired over folic acid due to reduced potential for masking vitamin B12 deficiency symptoms.

    Mixtures: Obstetrix EC
  6. Target

    S-adenosylmethionine synthase isoform type-1

    go.drugbank.com/bio_entities/BE0000407
    TargetEnzymeHumans

    Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis ...

    Synonyms: MATA1
  7. Drug

    Ceftriaxone

    go.drugbank.com/drugs/DB01212
    ApprovedInvestigational

    Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and strong...

    Products: CEFTRIAXONE EG
  8. Drug

    Acetylcysteine

    go.drugbank.com/drugs/DB06151
    ApprovedInvestigational

    Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONProducts: ACETILCISTEINA EG, ZIFLUVIS SOBRE X 600 MG
  9. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...

  10. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.